Show simple item record

dc.contributor.authorJones, C. M.
dc.contributor.authorO'Connor, H.
dc.contributor.authorO'Donovan, M.
dc.contributor.authorHayward, D.
dc.contributor.authorBlasko, A.
dc.contributor.authorHarman, R.
dc.contributor.authorMalhotra, S.
dc.contributor.authorDebiram-Beecham, I.
dc.contributor.authorAlias, B.
dc.contributor.authorBailey, A.
dc.contributor.authorBateman, A.
dc.contributor.authorCrosby, T. D. L.
dc.contributor.authorFalk, S.
dc.contributor.authorGollins, S.
dc.contributor.authorHawkins, M. A.
dc.contributor.authorKadri, S.
dc.contributor.authorLevy, S.
dc.contributor.authorRadhakrishna, Ganesh
dc.contributor.authorRoy, R.
dc.contributor.authorSripadam, R.
dc.contributor.authorFitzgerald, R. C.
dc.contributor.authorMukherjee, S.
dc.date.accessioned2022-10-26T12:58:53Z
dc.date.available2022-10-26T12:58:53Z
dc.date.issued2022en
dc.identifier.citationJones CM, O'Connor H, O'Donovan M, Hayward D, Blasko A, Harman R, et al. Use of a non-endoscopic immunocytological device (Cytosponge™) for post chemoradiotherapy surveillance in patients with oesophageal cancer in the UK (CYTOFLOC): A multicentre feasibility study. EClinicalMedicine. 2022 Nov;53:101664. PubMed PMID: 36187722. Pubmed Central PMCID: PMC9519482. Epub 2022/10/04. eng.en
dc.identifier.pmid36187722en
dc.identifier.doi10.1016/j.eclinm.2022.101664en
dc.identifier.urihttp://hdl.handle.net/10541/625700
dc.description.abstractBackground: Effective surveillance strategies are required for patients diagnosed with oesophageal squamous cell carcinoma (OSCC) or adenocarcinoma (OAC) for whom chemoradiotherapy (CRT) is used as a potentially-curative, organ-sparing, alternative to surgery. In this study, we evaluated the safety, acceptability and tolerability of a non-endoscopic immunocytological device (the Cytosponge™) to assess treatment response following CRT. Methods: This multicentre, single-arm feasibility trial took place in 10 tertiary cancer centres in the UK. Patients aged at least 16 years diagnosed with OSCC or OAC, and who were within 4-16 weeks of completing definitive or neo-adjuvant CRT, were included. Participants were required to have a Mellow-Pinkas dysphagia score of 0-2 and be able to swallow tablets. All patients underwent a single Cytosponge™ assessment in addition to standard of care (which included post-treatment endoscopic evaluation with biopsy for patients undergoing definitive CRT; surgery for those who received neo-adjuvant CRT). The primary outcome was the proportion of consented, evaluable patients who successfully underwent Cytosponge™ assessment. Secondary and tertiary outcomes included safety, study consent rate, acceptance rate, the suitability of obtained samples for biomarker analysis, and the comparative efficacy of Cytosponge™ to standard histology (endoscopy and biopsy or post-resection specimen) in assessing for residual disease. The trial is registered with ClinicalTrials.gov, NCT03529669. Findings: Between 18th April 2018 and 16th January 2020, 41 (42.7%; 95% confidence interval (CI) 32.7-53.2) of 96 potentially eligible patients consented to participate. Thirty-nine (95.1%, 95% CI 83.5-99.4) successfully carried out the Cytosponge™ procedure. Of these, 37 (95%) would be prepared to repeat the procedure. There were only two grade 1 adverse events attributed to use of the Cytosponge™. Thirty-five (90%) of the completed Cytosponge™ samples were suitable for biomarker analysis; 29 (83%) of these were concordant with endoscopic biopsies, three (9%) had findings suggestive of residual cancer on Cytosponge™ not found on endoscopic biopsies, and three (9%) had residual cancer on endoscopic biopsies not detected by Cytosponge™.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.eclinm.2022.101664en
dc.titleUse of a non-endoscopic immunocytological device (Cytosponge™) for post chemoradiotherapy surveillance in patients with oesophageal cancer in the UK (CYTOFLOC): A multicentre feasibility studyen
dc.typeArticleen
dc.contributor.departmentDepartment of Oncology, University of Cambridge, Cambridge, UKen
dc.identifier.journalEClinicalMedicineen
dc.description.noteen]
refterms.dateFOA2022-11-01T13:21:39Z


Files in this item

Thumbnail
Name:
36187722.pdf
Size:
1.378Mb
Format:
PDF
Description:
Identified with Open Access button

This item appears in the following Collection(s)

Show simple item record